GLS-010 not checked

Guangzhou Gloria Biosciences Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
in China
Next date
Phase 1/2 trial completes
Trials
2 active
5 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W. In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W.”In the company’s words, NCT05909436 on ClinicalTrials.gov
Tested for
Persistent, Recurrent, or Metastatic Cervical Cancer, Solid Tumor
Main trialPhase 3
“This is a randomized, double-blind, placebo-controlled phase III study to evaluate GLS-010 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer.”In the company’s words, NCT05798819 on ClinicalTrials.gov

Other drugs for Persistent, Recurrent, or Metastatic Cervical Cancer

All 266 drugs for Persistent, Recurrent, or Metastatic Cervical Cancer

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 31 Dec 2029 A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Phase 1/2Recruiting Dec 2026 Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors
Phase 3Unknown Jun 2025 GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)
Phase 1/2Unknown 1 Apr 2025 Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer
Phase 1Completed 28 Feb 2022 Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow GLS-010

Following is part of Solo: you see every change to GLS-010 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in